Chronic Graft-Versus-Host Disease Clinical Trial
Official title:
Randomized Controlled Trial of a Psychosocial Mobile Application (App) to Promote Coping for Patients With Chronic Graft-Versus-Host Disease (GVHD)
The purpose of this research study is to see whether a psychosocial mobile app called Horizons is effective at improving quality of life, symptom burden, psychological distress, and coping in patients living with chronic graft-versus host disease (GVHD)
Frequently patients living with chronic GVHD experience physical and emotional symptoms during the course of illness that impacts their quality of life. Patients also often report difficulty managing many of the tasks they need to do to manage their chronic GVHD. They also frequently have a lot of questions about chronic GVHD and the expected trajectory of this illness. The purpose of this research study is to see whether a psychosocial mobile app called Horizons is effective at improving quality of life, symptom burden, and psychological distress in patients with chronic GVHD - This study will randomly assign participants to either receiving Horizons plus usual care or usual care alone. - Enrolled participants will be on the research study for up to sixteen weeks and it is expected that about 120 people will take part in this research study. The Leukemia and Lymphoma Society is supporting this research by providing funding. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02991846 -
A Prospective Observational Study for Evaluating CGVHD
|
||
| Recruiting |
NCT02291770 -
Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells
|
Phase 3 | |
| Terminated |
NCT01226420 -
Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease
|
Phase 2 | |
| Active, not recruiting |
NCT02759731 -
Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
| Completed |
NCT01862965 -
Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus
|
Phase 2 | |
| Completed |
NCT02411474 -
Tear Cytokine Analysis as a Prediction or Diagnostic Marker in Ocular GvHD
|
N/A | |
| Completed |
NCT02040623 -
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
|
Phase 2 | |
| Active, not recruiting |
NCT01158105 -
Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)
|
Phase 2 | |
| Terminated |
NCT01903473 -
Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)
|
Phase 2 | |
| Active, not recruiting |
NCT01366092 -
Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
|
Phase 2 | |
| Recruiting |
NCT02918188 -
Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD
|
Phase 2 | |
| Recruiting |
NCT01765660 -
Mesenchymal Stem Cells for Treatment of Refractory Chronic Graft-versus-host Disease
|
Phase 2 | |
| Completed |
NCT01956903 -
Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell.
|
Phase 1/Phase 2 | |
| Terminated |
NCT03584516 -
GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04692376 -
MSC for Treatment of cGVHD After Allo-HSCT
|
Phase 2 | |
| Completed |
NCT02966301 -
Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide
|
Phase 2 | |
| Terminated |
NCT01898377 -
Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children
|
Phase 2 | |
| Recruiting |
NCT02611180 -
Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
|
||
| Recruiting |
NCT02669251 -
Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01161628 -
Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)
|
Phase 2 |